Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Rady Children'S Hospital Research Center has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The prosecution is currently limited to 1 distinct art unit, indicating that the pending matter is being reviewed by a specialized group within the biotechnology sector. This focused activity suggests a streamlined prosecution process for the organization, as it only needs to comply with the guidelines of a single technical unit. The concentration in 1 distinct art unit also allows for a more consistent technical argument across the organization's filings.
The 1 pending office action is being managed by 1 distinct examiner, SABOUR, GHAZAL. As the busiest examiner for the portfolio, this individual is the sole point of contact for the current pending workload. Practitioners can focus their strategy on the specific examination practices of this 1 distinct examiner, as there is no need to coordinate across multiple officials at this time. With only a single pending matter, the organization's immediate success in the Biotechnology & Pharmaceuticals area depends entirely on the decisions made by the assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABOUR, GHAZAL | 1 | 37.8% | +43.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16388614 | METHOD AND SYSTEM FOR RAPID GENETIC ANALYSIS | SABOUR, GHAZAL | 73d overdue |
| Art Unit | Apps |
|---|---|
| 1686 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16388614 | METHOD AND SYSTEM FOR RAPID GENETIC ANALYSIS | SABOUR, GHAZAL | 1686 | §103DP | Final Rejection | 73d overdue | Pending | Apr 18, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial